1. Scrip
  2. >>Business

CRISPR Patent Ruling Lifts Editas, Disappoints Intellia and CRISPR Therapeutics

US Decision Goes Against Nobel Prize Winners

 
• By Andrew McConaghie

A US decision to grant a CRISPR Cas9 patent to The Broad Institute lifts Editas but adds uncertainty to the IP estate of Intellia and CRISPR Therapeutics.

Emmanuelle Charpentier and Jennifer Doudna
Co-discoverers and Nobel Prize winners Emmanuelle Charpentier (left) and Jennifer Doudna have lost the patent case ruling • Source: Getty Images

A long-running legal battle over patents for CRISPR Cas9 gene editing has seen the US Patent Office’s Patent Trial and Appeal Board rule against the two scientists credited with discovering the technology, Jennifer Doudna of the University of California and the University of Vienna’s Emmanuelle Charpentier (collectively known as CVC), and in favor of Feng Zhang of the Broad Institute of MIT and Harvard.

Charpentier and Doudna were awarded the Nobel Prize in Chemistry two years ago for the discovery of the bacteria-derived gene-editing technique

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.